Highlights in bladder cancer from ASCO GU 2021
2 Views
administrator
07/18/23
Parminder Singh, MD, Mayo Clinic Hospital, Phoenix, AZ, shares his highlights in bladder cancer treatment from ASCO GU 2021. In particular, he discusses updates from the EV-301 trial (NCT03474107) investigating the use of enfortumab vedotin for patients with locally advanced or metastatic urothelial carcinoma. Dr Singh also talks about the Phase II/III QUILT-3.032 trial (NCT03022825) of a IL-15 superagonist, N-803, in BCG unresponsive non muscle invasive bladder cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.
-
Category
Show more
Facebook Comments
No comments found